drug
ozanimod hydrochloride
Marketedupdated 3mo agoby Celgene Corp
Approvedcommunity read0 votes
indications
investigational
IBD (Crohn's + UC)
all catalysts(0)
nothing on the calendar yet
Trials studying ozanimod hydrochloride
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 30, 2027
~1.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Sep 30, 2038compositionUS 11680050
- Sep 30, 2038compositionUS 11680050
- Sep 30, 2038compositionUS 11680050
- Mar 24, 2033compositionUS 8481573
- Mar 24, 2033compositionUS 8481573
- Mar 24, 2033compositionUS 8481573
- Nov 15, 2030method-of-use (U-3740)US 102398464.3y
- Nov 15, 2030method-of-use (U-3740)US 102398464.3y
- Nov 15, 2030method-of-use (U-3740)US 102398464.3y
- May 14, 2029compositionUS 87963182.7y
- May 14, 2029compositionUS 87963182.7y
- May 14, 2029compositionUS 87963182.7y
- May 14, 2029method-of-use (U-2774)US 93822172.7y
- May 14, 2029method-of-use (U-2774)US 93822172.7y
- May 14, 2029method-of-use (U-2774)US 93822172.7y
FDA exclusivities (3)
- Aug 30, 2027M-309Method (3y)1.0y
- Aug 30, 2027M-309Method (3y)1.0y
- Aug 30, 2027M-309Method (3y)1.0y
News(2)
- Abivax shares surge as worries subside over immune drug’s cancer riskAccording to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.biopharma_dive · 1mo ago
- cAMPfield lands $180M to build gut disease drugThe biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.biopharma_dive · 1mo ago
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that